Literature DB >> 6797865

Non-A, non-B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees: inactivation by formalin and heat.

H Yoshizawa, Y Itoh, S Iwakiri, K Kitajima, A Tanaka, T Tachibana, T Nakamura, Y Miyakawa, M Mayumi.   

Abstract

We have reported two kinds of viruslike particles derived from human sera that induced morphologically and serologically different types of non-A, non-B hepatitis in chimpanzees. A chimp serum containing one such agent capable of inducing a type of hepatitis with cytoplasmic tubular ultrastructures (non-A, non-B, type 1) was titrated for its infectivity in chimps. Two chimps who received 1 ml of a 10(-2) dilution of the original serum developed the characteristic morphological changes in the liver together with elevated serum transaminase levels, while the other two who received 1 ml of a 10(-4) dilution failed to show such changes. The two who escaped the infection were proven to be susceptible to the agent, because they developed non-A, non-B, type 1 hepatitis when they were challenged by 1 ml of a 10(-1) dilution of the same serum on the 23rd week after the first inoculation. One milliliter of a 10(-1) dilution containing more than 10 chimp infecting units were inactivated in the presence of 1/2000 formalin or by heating at 100 degrees C for 5 min and then given to four other chimps. None of them developed clinical or histologic evidence of non-A, non-B, type 1 hepatitis, thereby indicating that both formalin and heat could destroy the ability of the agent to induce this type of hepatitis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6797865

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  [Hepatitis non-A, non-B: epidemiologic, clinical, serologic and morphologic aspects].

Authors:  H P Spichtin
Journal:  Klin Wochenschr       Date:  1985-05-02

2.  Clinical, biochemical, serological, histological and ultrastructural features of liver disease in drug abusers.

Authors:  I V Weller; D Cohn; A Sierralta; M Mitcheson; M G Ross; L Montano; P Scheuer; H C Thomas
Journal:  Gut       Date:  1984-04       Impact factor: 23.059

3.  Correlation of serum antibody titers against hepatitis C virus core protein with clinical features by western blot (immunoblot) analysis using a recombinant vaccinia virus expression system.

Authors:  A Nishizono; M Hiraga; K Mifune; H Terao; T Fujioka; M Nasu; T Goto; J Misumi; M Moriyama; Y Arakawa
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

4.  Rationale for preoperative screening of anti-HCV antibody.

Authors:  Y Sakaguchi; S Inaba; J Yoshitake
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

5.  Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform.

Authors:  S M Feinstone; K B Mihalik; T Kamimura; H J Alter; W T London; R H Purcell
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

6.  Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.

Authors:  P N Lelie; H W Reesink; C J Lucas
Journal:  J Med Virol       Date:  1987-11       Impact factor: 2.327

7.  The agents of non-A, non-B viral hepatitis.

Authors:  D W Bradley
Journal:  J Virol Methods       Date:  1985-04       Impact factor: 2.014

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.